Related Experiment Videos
Clinical efficacy of Shankhapushpi and a herbo-mineral compound in type-II diabetes
Dhananjay V Patel1, Harimohan Chandola, Madhav Singh Baghel
1Lecturer, Post Graduate Department of Kaya Chikitsa, Government Akhandananda Ayurveda College, Ahmedabad, Gujarat, India.
Abstract:
Diabetic population is more than 245 million worldwide and expected to be b380 million by 2025. One of the main causes of increasing rate of diabetes is stress and tension in day-to-day life, disturbing the homeostasis of positive and negative emotions to initiate pathophysiology of stress-induced diabetes. In the present study, in Group A of 34 patients, a herbo-mineral compound containing Shuddha Shilajatu, Shuddha Guggulu, Vijayasara Ghana, Saptarangi Ghana, and Triphala Ghana was administered in the dose of 3 gm/day in three divided doses with luke-warm water before meal for the duration of 8 weeks, which significantly relieved symptoms (60.52%) like Prabhuta Mutrata (54.55%), Avila Mutrata (66.67%), Daurbalya (61.36%), Shrama (59.32%), etc. with fasting blood sugar (4.05%) and postprandial blood sugar (9.95%). In another series of 34 patients (Group B), where psychological health promoting drug Shankhapushpi was administered in the dose of 1.5 gm/day in three divided doses for 8 weeks along with herbo-mineral compound. The percentage relief was found to be more better on symptoms (71.13%) like Prabhuta Mutrata (76.92%), Avila Mutrata (83.33%), Daurbalya (75%), Shrama (70.37%), fasting blood sugar (18.04%) and postprandial blood sugar (27.75%). Group B showed better results on psychological parameters like disturbed Manasabhava (29.16%) and Brief Psychiatry Rating Scale (38.28%). The high significance of χ(2) (15.50) on overall effect of therapy indicated better results in group B.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Oral Hypoglycemic Agents: Biguanides and Glitazones
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type II Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Dipeptidyl Peptidase 4 Inhibitors